ClinicalTrials.gg
TerminatedNCT06999603INVENTUpdated Sep 14, 2026Results posted

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

A Phase 2 interventional study of SNG001 and Placebo in Viral Pneumonia, sponsored by Synairgen Research Ltd.. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Synairgen Research Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was stopped due to significantly low patient recruitment rate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Pneumonia, Viral with a site in United States — 5 open to participants now, 6 under way, 3 of them phase 3. Pneumonia, Viral · United States.

Enrollment
19th of 27
11 · median 50
Started
2025
with 2 others
Phase 2
7 of 33
none open now
Registered
31st of 33
by date

Among the 33 studies in Pneumonia, Viral with a site in United States, this one is the 19th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 2, and was the 31st registered.

Pneumonia, Viral

156 studies on the registry are indexed under Pneumonia, Viral; 13 are open to participants now.

Browse Pneumonia, Viral studies →

Open to participants now

5 of the 33 studies in Pneumonia, Viral with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Pneumonia, Viral studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pneumonia, Viral with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied.

The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo.

In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital.

In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.

03

Conditions studied

  • Viral Pneumonia

Keywords

  • Influenza
  • Respiratory Syncytial Virus
  • Rhinovirus
  • Adenovirus
  • Human Metapneumovirus
  • Coronavirus
  • Intubated
  • Mechanically ventilated
  • Interferon
  • Intensive care
  • SARS-CoV-2
  • Parainfluenza
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part 1 Inclusion Criteria:

To be eligible for randomisation into Part 1 of this study, each participant must fulfil the following criteria:

  1. or legal representative's consent obtained.
  2. Patients ≥50 years of age at the time of consent.
  3. Patient admitted to the ICU and requiring invasive mechanical ventilation (IMV) due to a respiratory virus infection.
  4. Presence of Influenza A (Flu A), Influenza B (Flu B), respiratory syncytial virus (RSV), rhinovirus (RV), adenovirus, parainfluenza, human metapneumovirus (HMPV), or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a nose swab sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., reverse transcription polymerase chain reaction [RT-PCR]).
  5. Time from intubation to administration of first dose of study medication ≤48 hours.
  6. Women of must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \<55 years old.

Part 1 Exclusion Criteria:

A participant must not be randomised into Part 1 of the study if they meet any of the following criteria:

  1. Expected termination of IMV within 24 hours from the time of randomisation
  2. \<24 hours.
  3. Liver failure ( C).
  4. Severe congestive heart failure ( [NYHA] IV).
  5. Receipt of lung transplant.
  6. Known or suspected active tuberculosis, or infection with other mycobacteria
  7. Known or suspected active systemic fungal infection.
  8. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.
  9. Need for long-term mechanical ventilation prior to ICU admission.
  10. Use of inhaled sedation.
  11. Presence of tracheostomy or laryngectomy.
  12. Requirement for airway pressure release ventilation mode.
  13. History of to natural or recombinant IFNβ or to any of the in the drug preparation.
  14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
  15. Participation in previous clinical studies of SNG001.
  16. Current or previous participation in another clinical study where the participant has received a dose of an Medicinal Product (IMP) containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
  17. Known or suspected pregnancy.
  18. Females who are breast-feeding or lactating.
  19. Immunocompromising condition, including:

    • Established acquired immune deficiency syndrome (AIDS) defined as a cluster of differentiation 4 (CD4) count \<200 cells/microL, and/or the presence of any AIDS-defining condition;
    • Haematological ;
    • Bone marrow transplantation; or
    • therapy, including:
    • Cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy), immune-cell depleting therapy, immunosuppressive therapy for disorders, medications for prevention of organ transplantation rejection, administered within 6 months prior to randomisation; or
    • >20 mg of prednisone or equivalent per day administered continuously for >14 days prior to randomisation.
  20. Severe chronic lung disease requiring home oxygen therapy, including , asthma, cystic fibrosis, or pulmonary fibrosis.

Part 2 Inclusion Criteria:

To be eligible for randomisation into Part 2 of this study, each participant must fulfil the following criteria:

1.a Patients ≥18 and \<50 years of age at the time of consent, with an immunocompromising condition, including:

  • Solid tumour malignancy undergoing cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy);
  • Haematological malignancy in remission, with or without maintenance therapy;
  • Immunosuppressive therapy for autoimmune disease;
  • Therapy for prevention of organ transplant rejection;
  • Corticosteroids >20 mg of prednisone or equivalent per day, administered continuously for >14 days prior to randomisation or

    1. b Patients ≥50 years of age at the time of consent, with or without an immunocompromising condition (as defined above).
    2. Patient admitted to the ICU and requiring IMV due to a respiratory virus infection.
    3. Presence of Flu A, Flu B, RSV, RV, adenovirus, parainfluenza, HMPV, or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a Lower Respiratory Tract sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., RT-PCR).
    4. Time from intubation to administration of first dose of study medication ≤48 hours.
    5. Informed consent or legal representative's consent obtained.
    6. Women of childbearing potential must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \<55 years old.

Part 2 Exclusion Criteria:

A participant must not be randomised into Part 2 of the study if they meet any of the following criteria:

  1. Expected termination of IMV within 24 hours from the time of randomisation.
  2. Life expectancy \<24 hours.
  3. Liver failure (Child-Pugh C).
  4. Severe congestive heart failure (NYHA IV).
  5. Receipt of lung transplant.
  6. Known or suspected active tuberculosis, or infection with other mycobacteria.
  7. Known or suspected systemic fungal infection.
  8. Immunocompromising condition, including:

    • Haematological malignancy requiring induction or consolidation therapy within 3 months prior to randomisation;
    • Bone marrow transplant within 6 months prior to randomisation;
    • Solid organ transplant within 6 months prior to randomisation;
    • Corticosteroids >75 mg of prednisone or equivalent per day, administered continuously for >7 days prior to randomisation;
    • Methotrexate therapy at randomisation, if the indication is chemotherapy for cancer;
    • Chimeric antigen receptor (CAR)-T cell therapy, administered within 3 months prior to randomisation;
    • Ibrutinib or alemtuzumab, administered within 3 months prior to randomisation;
    • Neutropenia \<500/mm3 not due to sepsis;
    • Clinical presentation consistent with severe bone marrow suppression or pancytopenia;pancytopenia;
    • Established AIDS, defined as a \<200 cells/microL, and/or the presence of any AIDS-defining condition.
  9. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.
  10. Need for long-term mechanical ventilation prior to ICU admission.
  11. Use of inhaled sedation.
  12. Presence of tracheostomy or laryngectomy
  13. History of hypersensitivity to natural or recombinant IFNβ or to any of the excipients in the drug preparation.
  14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
  15. Participation in previous clinical studies of SNG001.
  16. Current or previous participation in another clinical study where the participant has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
  17. Known or suspected pregnancy.
  18. Females who are breast-feeding or lactating.
  19. Severe chronic lung disease requiring home oxygen therapy, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Part 1 Safety Evaluation of SNG001

    Participants will inhale a dose of SNG001 via the nebuliser, once a day for up to 14 days. A first, single syringe, low-dose cohort may be followed by an optional second cohort utilising a two-syringe dose.

    Drug: SNG001

  • Placebo comparator
    Part 1 Safety Evaluation of SNG001 (Placebo)

    Participants will inhale a dose of placebo matched to SNG001 (only excipients of the SNG001 solution) via the nebuliser, once a day for up to 14 days.

    Drug: Placebo

  • Experimental
    Part 2 Efficacy Evaluation of SNG001

    Participants will inhale the higher (two-syringe) dose of SNG001 via the nebuliser, once a day for up to 14 days.

    Drug: SNG001

  • Placebo comparator
    Part 2 Efficacy evaluation of SNG001 (Placebo)

    Participants will inhale a dose of placebo matched to SNG001 (only excipients of the SNG001 solution) via the nebuliser, once a day for up to 14 days

    Drug: Placebo

Interventions

  • DrugSNG001

    Drug pages: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001

    SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing drug product solution of IFNβ 1a.

  • DrugPlacebo

    The placebo nebuliser solution is presented in glass syringes containing solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).

06

What researchers measure

Primary outcomes

  1. Part 1: AE and SAE Severity

    The occurrence and severity of AEs and serious adverse events (SAEs), including pre-specified respiratory and cardiovascular deteriorations.

    Time frame: Up to 28 days from randomisation

  2. Part 2: All-cause Mortality

    All deaths recorded on study

    Time frame: Within 28 days from randomisation

Secondary outcomes

  1. Part 2: AE and SAE Severity

    The occurrence and severity of AEs and SAEs, including pre-specified respiratory and cardiovascular deteriorations.

    Time frame: Up to 42 days from randomisation

  2. Part 2: Change in mSOFA From Baseline

    Change from baseline in modified Sequential Organ Failure Assessment (mSOFA) score during ICU (intensive Care Unit) stay.

    Time frame: Up to 14 days

  3. Part 2: Time to Extubation

    Time to extubation.

    Time frame: Up to 28 days from randomisation

  4. Part 2: Number of Ventilator Free Days

    Ventilator-free days over 28 days from randomisation

    Time frame: Up to 28 days from randomisation

  5. Part 2: Duration of Stay in ICU

    Duration of ICU stay measured from time of admission until discharge.

    Time frame: Up to 28 days from randomisation

  6. Part 2: Duration of Stay in Hospital

    Duration of hospital stay measured from time of admission until discharge.

    Time frame: Up to 28 days from randomisation

  7. Part 2: Change in OSCI From Baseline

    Change in Ordinal Scale for Clinical Improvement (OSCI) score from baseline to 7, 10, 14 and 28 days post randomisation.

    Time frame: Up to 28 days from randomisation

  8. Part 2: Time to First Negative Virus Test

    Time to first negative virus test in tracheal aspirates.

    Time frame: Up to 14 days from randomisation

  9. Part 2: Change in IFNβ Levels From Baseline

    Change from baseline in levels of IFNβ dependent biomarkers in tracheal aspirates

    Time frame: Up to 14 days from randomisation

  10. Part 2: No Organ Support

    Alive and free of organ support

    Time frame: At 28 days from randomisation and at 28 days post final dose

  11. Part 2: All Cause Mortality

    All deaths recorded post final dose

    Time frame: Within 28 days post final dose

07

Results

Posted Sep 14, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)Part 2 Efficacy Evaluation of SNG001Part 2 Efficacy Evaluation of SNG001 (Placebo)
Started8300
Completed8300
Not completed0000

Outcome measures

PrimaryPart 1: AE and SAE Severity

The occurrence and severity of AEs and serious adverse events (SAEs), including pre-specified respiratory and cardiovascular deteriorations.

Time frame:
Up to 28 days from randomisation
Reported as:
Count of participants · Participants
Part 1: AE and SAE Severity
ParticipantsPart 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)
Any TEAE82
Mild TEAE22
Moderate TEAE22
Severe TEAE72
Any serious TEAE72
Any fatal TEAE41
Any related fatal TEAE00
Any TEAE related to study treatment10
Any TEAE leading to discontinuation of study treatment10
Any TEAE of note00
PrimaryPart 2: All-cause Mortality

All deaths recorded on study

Time frame:
Within 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: AE and SAE Severity

The occurrence and severity of AEs and SAEs, including pre-specified respiratory and cardiovascular deteriorations.

Time frame:
Up to 42 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Change in mSOFA From Baseline

Change from baseline in modified Sequential Organ Failure Assessment (mSOFA) score during ICU (intensive Care Unit) stay.

Time frame:
Up to 14 days

No measurements were reported for this outcome.

SecondaryPart 2: Time to Extubation

Time to extubation.

Time frame:
Up to 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Number of Ventilator Free Days

Ventilator-free days over 28 days from randomisation

Time frame:
Up to 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Stay in ICU

Duration of ICU stay measured from time of admission until discharge.

Time frame:
Up to 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Stay in Hospital

Duration of hospital stay measured from time of admission until discharge.

Time frame:
Up to 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Change in OSCI From Baseline

Change in Ordinal Scale for Clinical Improvement (OSCI) score from baseline to 7, 10, 14 and 28 days post randomisation.

Time frame:
Up to 28 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Time to First Negative Virus Test

Time to first negative virus test in tracheal aspirates.

Time frame:
Up to 14 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: Change in IFNβ Levels From Baseline

Change from baseline in levels of IFNβ dependent biomarkers in tracheal aspirates

Time frame:
Up to 14 days from randomisation

No measurements were reported for this outcome.

SecondaryPart 2: No Organ Support

Alive and free of organ support

Time frame:
At 28 days from randomisation and at 28 days post final dose

No measurements were reported for this outcome.

SecondaryPart 2: All Cause Mortality

All deaths recorded post final dose

Time frame:
Within 28 days post final dose

No measurements were reported for this outcome.

Adverse events

Collected over All adverse events for Part 1 of the study were collected 28 days from randomisation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Safety Evaluation of SNG0014/8 (50%)7/8 (87.5%)8/8 (100%)
Part 1 Safety Evaluation of SNG001 (Placebo)1/3 (33.3%)2/3 (66.7%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventPart 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)
Respiratory failureRespiratory, thoracic and mediastinal disorders2/81/3
PneumoniaRespiratory, thoracic and mediastinal disorders1/81/3
Cardiac failureCardiac disorders0/81/3
Cardiac failure acuteCardiac disorders0/81/3
Multiple organ dysfunction syndromeGeneral disorders2/80/3
Alanine aminotransferase increasedInvestigations1/80/3
BronchospasmRespiratory, thoracic and mediastinal disorders1/80/3
Hepatic steatosisGastrointestinal disorders1/80/3
Herpes simplex meningoencephalitisNervous system disorders1/80/3
Klebsiella urinary tract infectionInfections and infestations1/80/3
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPart 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)
Respiratory failureRespiratory, thoracic and mediastinal disorders2/81/3
PneumoniaRespiratory, thoracic and mediastinal disorders1/81/3
ArthralgiaMusculoskeletal and connective tissue disorders0/81/3
Cardiac failureCardiac disorders0/81/3
Cardiac failure acuteCardiac disorders0/81/3
Oral herpesSkin and subcutaneous tissue disorders0/81/3
Pleural effusionRespiratory, thoracic and mediastinal disorders0/81/3
Respiratory acidosisRespiratory, thoracic and mediastinal disorders0/81/3
Superficial vein thrombosisBlood and lymphatic system disorders0/81/3
Multiple organ dysfunction syndromeGeneral disorders2/80/3

Baseline characteristics

Part 2 was not conducted. Study was terminated due to significantly low patient recruitment rate.

Age, Continuous
Age, Continuous(Years)Part 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)Part 2 Efficacy Evaluation of SNG001Part 2 Efficacy Evaluation of SNG001 (Placebo)Total
Mean66.5 ± 13.9563.67 ± 11.72——65.09 ± 13.13
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)Part 2 Efficacy Evaluation of SNG001Part 2 Efficacy Evaluation of SNG001 (Placebo)Total
Female42006
Male41005
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)Part 2 Efficacy Evaluation of SNG001Part 2 Efficacy Evaluation of SNG001 (Placebo)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American40004
White42006
More than one race00000
Unknown or Not Reported01001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Safety Evaluation of SNG001Part 1 Safety Evaluation of SNG001 (Placebo)Part 2 Efficacy Evaluation of SNG001Part 2 Efficacy Evaluation of SNG001 (Placebo)Total
Hispanic or Latino01001
Not Hispanic or Latino820010
Unknown or Not Reported00000
08

Study locations

10 sites
  • Emory University
    Atlanta, Georgia 30308, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Sinai-Grace Hospital
    Detroit, Michigan 48235, United States
  • Mercy St. Vincent Medical Center
    Toledo, Ohio 43608, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239-3098, United States
  • Aberdeen Royal Infirmary
    Aberdeen, AB25 2ZN, United Kingdom
  • Bradford Royal Infirmary
    Bradford, BD9 6RJ, United Kingdom
  • University College London Hospital
    London, NW1 2PG, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Mar 2026, 6 months.

Results were first posted in Sep 2026, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartActual
Sep 2, 2025
Primary completionActual
Mar 13, 2026
CompletionActual
Mar 13, 2026
Results first posted
Sep 14, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06999603
Lead sponsor
Synairgen Research Ltd.
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Sep 2, 2025
Primary completion
Mar 13, 2026
Completion
Mar 13, 2026
Results posted
Sep 14, 2026
Last update
Sep 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001

Start the discussion